Increased Intracranial Pressure

Earn CME/CE in your profession:


Continuing Education Activity

The pressure in the cranial vault is measured in millimeters of mercury (mm Hg) and is normally less than 20 mm Hg. The cranium is a rigid structure that contains 3 main components: brain, cerebrospinal fluid, and blood. Any increase in the volume of its contents will increase the pressure within the cranial vault. An increase in the volume of one component will result in a decrease in volume in one or two of the other components. The clinical implication of the change in volume of the component is a decrease in cerebral blood flow or herniation of the brain. This activity reviews the cause, pathophysiology, and presentation of increased intracranial pressure and highlights the role of the interprofessional team in its management.

Objectives:

  • Describe the causes of increased intracranial pressure.
  • Review the clinical presentation of a patient with increased intracranial pressure.
  • Summarize the treatment of increased intracranial pressure.
  • Explain modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by increased intracranial pressure.

Introduction

Intracranial hypertension (IH) is a clinical condition that is associated with an elevation of the pressures within the cranium. The pressure in the cranial vault is measured in millimeters of mercury (mm Hg) and is normally less than 20 mm Hg.

The cranium is a rigid structure that contains three main components: brain, cerebrospinal fluid, and blood. Any increase in the volume of its contents will increase the pressure within the cranial vault. The Monroe-Kellie Doctrine states that the contents of the cranium are in a state of constant volume.[1] That is, the total volumes of the brain tissues, cerebrospinal fluid (CSF), and intracranial blood are fixed. An increase in the volume of one component will result in a decrease in volume in one or two of the other components. The clinical implication of the change in volume of the component is a decrease in cerebral blood flow or herniation of the brain.

CSF is a clear fluid found in the subarachnoid spaces and ventricles that cushions the brain and spinal cord. It is secreted by the choroid plexus in the lateral ventricles, travels to the third ventricle via the foramen of Monroe. From the third ventricle, CSF reaches the fourth ventricle through the aqueduct of Sylvius. From here, it flows into the subarachnoid space via the foramina of Magendie and Luschka and is eventually reabsorbed into the dural venous sinuses by arachnoid granulation.

Etiology

The causes of increased intracranial pressure (ICP) can be divided based on the intracerebral components causing elevated pressures:

Increase in brain volume

Generalized swelling of the brain or cerebral edema from a variety of causes such as trauma, ischemia, hyperammonemia, uremic encephalopathy, and hyponatremia

Mass Effect

  • Hematoma
  • Tumor
  • Abscess
  • Infarct

Increase in Cerebrospinal Fluid

  • Increased production of CSF
  • Choroid plexus tumor

Decreased Reabsorption of CSF

  • Obstructive hydrocephalus
  • Meningeal inflammation or granulomas

Increase in Blood Volume

  • Increased cerebral blood flow during hypercarbia, aneurysms
  • Venous stasis from
  • Venous sinus thromboses,
  • Elevated central venous pressures, e.g., heart failure

Other Causes

  • Idiopathic or benign intracranial hypertension
  • Skull deformities such as craniosynostosis
  • Hypervitaminosis A, tetracycline use

Epidemiology

The true incidence of intracranial hypertension is unknown. The Centers for Disease Control and Prevention (CDC) estimates that in 2010, 2.5 million people sustained a traumatic brain injury (TBI). TBI is associated with increased ICP. ICP monitoring is recommended for all patients with severe TBI. Studies of American-based populations have estimated that the incidence of idiopathic intracranial hypertension (IIH) ranges from 0.9 to 1.0 per 100,000 in the general population, increasing in women that are overweight.[2]

Pathophysiology

The harmful effects of intracranial hypertension are primarily due to brain injury caused by cerebral ischemia. Cerebral ischemia is the result of decreased brain perfusion secondary to increased ICP. Cerebral perfusion pressure (CPP) is the pressure gradient between mean arterial pressure (MAP) and intracranial pressure (CPP = MAP - ICP).[3] CPP = MAP - CVP if central venous pressure is higher than intracranial pressure. CPP target for adults following severe traumatic brain injury is recommended at greater than 60 to 70 mm Hg, and a minimum CPP greater than 40 mm Hg is recommended for infants, with very limited data on normal CPP targets for children in between.

Cerebral autoregulation is the process by which cerebral blood flow varies to maintain adequate cerebral perfusion. When the MAP is elevated, vasoconstriction occurs to limit blood flow and maintain cerebral perfusion. However, if a patient is hypotensive, cerebral vasculature can dilate to increase blood flow and maintain CPP.

History and Physical

Clinical suspicion for intracranial hypertension should be raised if a patient presents with the following signs and symptoms: headaches, vomiting, and altered mental status varying from drowsiness to coma. Visual changes can range from blurred vision, double vision from cranial nerve defects, photophobia to optic disc edema, and eventually optic atrophy. Infants in whom the anterior fontanelle is still open may have a bulge overlying the area.

Cushing triad is a clinical syndrome consisting of hypertension, bradycardia, and irregular respiration and is a sign of impending brain herniation. This occurs when the ICP is too high the elevation of blood pressure is a reflex mechanism to maintain CPP. High blood pressure causes reflex bradycardia and brain stem compromise affecting respiration. Ultimately the contents of the cranium are displaced downwards due to the high ICP, causing a phenomenon known as herniation which can be potentially fatal.[4]

Evaluation

The evaluation of increased ICP should include detailed history taking, physical examination, and ancillary studies.

It is extremely important to identify increased ICP as early as possible to prevent herniation and death. For example malignant middle cerebral artery stroke presenting with increased ICP. Malignant middle cerebral artery stroke is seen more commonly in the younger population. Usually, these patients are admitted to the ICU setting. Following the neurological exam closely is very important. Usually, there is an altered mental status and development of a fixed and dilated pupil. Patients presenting with findings suggestive of cerebral insult should undergo computed tomography (CT) scan of the brain; this can show the edema, which is visible as areas of low density and loss of gray/white matter differentiation, on an unenhanced image. There can also be an obliteration of the cisterns and sulcal spaces. A CT scan can also reveal the cause in some cases. If flattened gyri or narrowed sulci, or compression of the ventricles, is seen, this suggests increased ICP. Serial CT scans are used to monitor the progression or improvement of the edema.[5]

A funduscopic exam can reveal papilledema which is a tell-tale sign of raised ICP as the cerebrospinal fluid is in continuity with the fluid around the optic nerve.

Imaging- a computed tomography (CT) of the head or magnetic resonance imaging (MRI) can reveal signs of raised ICP such as enlarged ventricles, herniation, or mass effect from causes such as tumors, abscesses, and hematomas, among others.

Measurement of Opening Pressure with a Lumbar Puncture

In this procedure, a needle is introduced in the subarachnoid space. This can be connected to a manometer to give the pressure of the CSF prior to drainage. A measurement greater than 20 mm Hg is suggestive of raised ICP. Brain imaging should precede an LP because LP can cause a sudden and rapid decrease in ICP and the sudden change in volume can lead to herniation.

ICP Monitoring[6]

Several devices can be used for ICP monitoring.

The procedure involves the placement of a fiber optic catheter into the brain parenchyma to measure the pressure transmitted to the brain tissue.

External Ventricular Drain (EVD)

A drain placed directly into the lateral ventricles can be connected to a manometer to give a reading for the pressure in the ventricles.

Optic Nerve Sheath Diameter (ONSD)[7]

The use of ultrasound to measure the diameter of the optic nerve sheath has been recently identified as a method to indicate raised ICP. This is usually measured 3 mm behind the globe with 2–3 measurements taken in each eye. The threshold for denoting elevated ICP usually ranges from 0.48 cm to 0.63 cm.

Treatment / Management

Assessment and management of the airway, specifically breathing and circulation should always be the priority.[8]

Management principles should be targeted toward:

  • Maintenance of cerebral perfusion pressure by raising MAP 
  • Treatment of the underlying cause.
  • Lowering of ICP.[9]

Measures to lower ICP include:[10]

  • Elevation of the head of the bed to greater than 30 degrees.
  • Keep the neck midline to facilitate venous drainage from the head.
  • Hypercarbia lowers serum pH and can increase cerebral blood flow contributing to rising ICP, hence hyperventilation to lower pCO2 to around 30 mm Hg can be transiently used.
  • Osmotic agents can be used to create an osmotic gradient across blood thereby drawing fluid intravascularly and decreasing cerebral edema. Mannitol was the primary agent used at doses of 0.25 to 1 g/kg body weight and is thought to exert its greatest benefit by decreasing blood viscosity and to a lesser extent by decreasing blood volume. Side effects of mannitol use are eventual osmotic diuresis and dehydration as well as renal injury if serum osmolality exceeds 320 mOsm.[11] Steroids are indicated to reduce ICP in intracranial neoplastic tumors, but not in traumatic brain injury.
  • Three percent hypertonic saline is also commonly used to decrease cerebral edema and can be administered as a 5 ml/kg bolus or a continuous infusion, monitoring serum sodium levels closely. It is considered relatively safe while serum sodium is < than 160mEq/dl or serum osmolality is less than 340 mOsm.[12]
  • Drugs of the carbonic anhydrase inhibitor class, such as acetazolamide, can be used to decrease the production of CSF and is used to treat idiopathic intracranial hypertension.
  • Lumbar punctures, besides being diagnostic, can be used to drain CSF thus reducing the ICP. The limitation to this is raised ICP secondary to mass effect with a possible risk of herniation if the CSF pressure drops too low.
  • Similar to a lumbar puncture, an EVD can also be used to not only monitor ICP but also to drain CSF.
  • Optic nerve fenestrations can be performed for patients with chronic idiopathic hypertension at a risk of blindness. Neurosurgical shunts such as ventriculoperitoneal or lumbar-peritoneal shunts can divert CSF to another part of the body from where it can be reabsorbed.[13]
  • Intravenous (IV) glyburide is being investigated in the prevention of hemispheric stroke edema. It acts by inhibiting SUR1 receptors.[14]
  • Barbiturates can be considered in cases where sedation and usual methods of treatment are not successful in reducing the ICP.[15]
  • Therapeutic hypothermia to 32-35 degrees Celcius can be used in a refractory rise in ICP not responding to hyperosmolar therapy and barbiturate coma. But its use has been questioned in recent days.
  • A decompressive craniectomy is a neurosurgical procedure wherein a part of the skull is removed, and dura lifted, allowing the brain to swell without causing compression.[16] It is usually considered as a last resort when all other ICP lowering measures have failed.

Differential Diagnosis

  • Acute nerve injury
  • Blood dyscrasias and stroke
  • Hydrocephalus
  • Intracranial hemorrhage
  • Intracranial epidural abscess
  • Lyme disease
  • Meningioma
  • Migraine variants
  • Subarachnoid hemorrhage

Prognosis

Prognosis depends on the underlying etiology and severity of the presentation. Benign intracranial hypertension does not increase the risk of death rate by itself; rather, the death rate is increased by morbid obesity which is a common association with benign intracranial hypertension. Visual loss is significant morbidity in IIH.

Deterrence and Patient Education

Any patient likely to develop increased intracranial pressure should be educated regarding the warning symptoms of the same including persistent headaches and vomiting.

Pearls and Other Issues

A patient who presents with a headache, vomiting, and blurred vision should be evaluated for neurologic deficits and receive head imaging to rule out the causes of intracranial hypertension.

All patients with severe TBI (Glasgow coma scale of 3 to 8 on initial presentation) should follow the latest guidelines on the management of severe TBI that includes monitoring of ICP, maintenance of CPP greater than 60 to 70 mm Hg for adults, and treatment of ICP greater than 22 mm Hg.

Enhancing Healthcare Team Outcomes

The clinical presentation of increased intracranial pressure can easily be mistaken for other issues, such as intoxication, stroke, infection, or post-ictal state. It requires a high index of suspicion, particularly in milder cases. In more severe cases, close neurological monitoring and consultation with neurology and neurosurgery are important. Communication regarding indications/risks/contraindications for ICP monitoring or craniotomy needs to be ongoing, particularly with respect to goals of care. Nursing care must pay close attention to changes in neurologic status, any change in vitals such as an increasingly erratic heart rate, development of bradycardia, accurate and equal intake and output when having diuresis, and maintenance of proper blood pressure. As the patient recovers, physical therapy, occupational therapy, and speech-language pathology can help the patient maximize function after the brain injury and evaluate patient safety both before and after discharge. 

Patient education regarding avoidance of future complications should come from all team members, with social work involvement to ensure home safety after discharge, and the patient's primary care provider should be updated, to ensure appropriate follow-up. In cases of vasogenic edema due to brain tumor, both oncology, radiation oncology, and neurosurgery should be consulted to co-manage the evaluation and management of the neoplasm, determine the best treatment for the tumor (resection/radiation/palliation) based on the tumor type/stage, and follow up with the patient after discharge. And, finally, the patient and the patient's family and care providers should be educated about what to watch for that may suggest the need for re-evaluation because of recurrence, or complications from any of the interventions.


Article Details

Article Author

Venessa Pinto

Article Author

Prasanna Tadi

Article Editor:

Adebayo Adeyinka

Updated:

8/4/2021 2:48:22 PM

References

[1]

Mokri B, The Monro-Kellie hypothesis: applications in CSF volume depletion. Neurology. 2001 Jun 26     [PubMed PMID: 11425944]

[2]

Re-evaluating the Incidence of Idiopathic Intracranial Hypertension in an Era of Increasing Obesity., Kilgore KP,Lee MS,Leavitt JA,Mokri B,Hodge DO,Frank RD,Chen JJ,, Ophthalmology, 2017 May     [PubMed PMID: 28187976]

[3]

Mount CA,M Das J, Cerebral Perfusion Pressure StatPearls. 2021 Jan;     [PubMed PMID: 30725956]

[4]

Munakomi S,M Das J, Brain Herniation StatPearls. 2021 Jan;     [PubMed PMID: 31194403]

[5]

Nehring SM,Tenny S, Cerebral Edema 2019 Jan;     [PubMed PMID: 30725957]

[6]

Munakomi S,M Das J, Intracranial Pressure Monitoring StatPearls. 2021 Jan;     [PubMed PMID: 31194438]

[7]

Changa AR,Czeisler BM,Lord AS, Management of Elevated Intracranial Pressure: a Review. Current neurology and neuroscience reports. 2019 Nov 26;     [PubMed PMID: 31773291]

[8]

Management of pediatric traumatic brain injury., Mtaweh H,Bell MJ,, Current treatment options in neurology, 2015 May     [PubMed PMID: 25854651]

[9]

Medical Management of the Severe Traumatic Brain Injury Patient., Marehbian J,Muehlschlegel S,Edlow BL,Hinson HE,Hwang DY,, Neurocritical care, 2017 Dec     [PubMed PMID: 28573388]

[10]

MANAGEMENT OF SEVERE TRAUMATIC BRAIN INJURY (First 24 hours)., Geeraerts T,Velly L,Abdennour L,Asehnoune K,Audibert G,Bouzat P,Bruder N,Carrillon R,Cottenceau V,Cotton F,Courtil-Teyssedre S,Dahyot-Fizelier C,Dailler F,David JS,Engrand N,Fletcher D,Francony G,Gergelé L,Ichai C,Javouhey E,Leblanc PE,Lieutaud T,Meyer P,Mirek S,Orliaguet G,Proust F,Quintard H,Ract C,Srairi M,Tazarourte K,Vigué B,Payen JF,, Anaesthesia, critical care & pain medicine, 2017 Dec 27     [PubMed PMID: 29288841]

[11]

Hyperosmolar therapy in the treatment of severe head injury in children: mannitol and hypertonic saline., Knapp JM,, AACN clinical issues, 2005 Apr-Jun     [PubMed PMID: 15876888]

[12]

Role of hypertonic saline and mannitol in the management of raised intracranial pressure in children: A randomized comparative study., Upadhyay P,Tripathi VN,Singh RP,Sachan D,, Journal of pediatric neurosciences, 2010 Jan     [PubMed PMID: 21042500]

[13]

Idiopathic intracranial hypertension., Friedman DI,Jacobson DM,, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2004 Jun     [PubMed PMID: 15179068]

[14]

Sheth KN,Elm JJ,Molyneaux BJ,Hinson H,Beslow LA,Sze GK,Ostwaldt AC,Del Zoppo GJ,Simard JM,Jacobson S,Kimberly WT, Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet. Neurology. 2016 Oct;     [PubMed PMID: 27567243]

[15]

Velle F,Lewén A,Howells T,Nilsson P,Enblad P, Temporal effects of barbiturate coma on intracranial pressure and compensatory reserve in children with traumatic brain injury. Acta neurochirurgica. 2021 Feb;     [PubMed PMID: 33341913]

[16]

Smith M, Refractory Intracranial Hypertension: The Role of Decompressive Craniectomy. Anesthesia and analgesia. 2017 Dec     [PubMed PMID: 28806209]